Medisch Centrum Haagland (Westeinde Hospital) newest customer to leverage IntraOp's advanced intraoperative electron radiation therapy system

Sunnyvale, California; September 26, 2006 IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced that it has delivered a Mobetron® to the MCH Westeinde Hospital in The Hague. MCH is one of the major cancer centers in The Netherlands and treats more than 2000 patients each year. The Mobetron system is designed exclusively for intraoperative electron radiation therapy (IOERT), which is the direct application of radiation to a tumor while a patient is undergoing cancer surgery. This will be only the second IOERT system in The Netherlands.

Medical Center Haaglanden (MCH) is the second Dutch Hospital to take delivery of a Mobetron. Dr. Joost van der Sijp, the oncology surgeon, and Professor Doctor Henk Struikmans, the radiation oncologist, are responsible for developing the IOERT program at MCH. They state: "We are looking forward to getting our Mobetron in clinical operation. In addition to using IOERT for rectal cancer, we plan to use it for breast conserving therapy in early stage breast cancer patients."

"It is a privilege to be working with an institution like MCH," said Donald A. Goer, President and Chief Executive Officer of IntraOp. "MCH has a strong commitment to integrate IOERT into their cancer program. It is centers like MCH that make a real difference in the lives of the patients they treat."

With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without the costly renovations required to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects.

About Medical Center Haaglanden

Medical Center Haaglanden in The Hague and Leidschendam is one of eighteen comprehensive cancer centers in the Netherlands that provide cancer treatment to the 16 million people in the Netherlands. It will be the second center that offers intraoperative electron beam treatment for cancer patients in the Netherlands. Of note, the Mobetron was originally going to be purchased with private funds from an investment group, but the Health Care Institutions subsequently agreed to financially support this initiative.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.